Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Granting a Marketing Authorisation for Tebentafusp

It is intended for the treatment of adult patients with unresectable or metastatic HLA A*02:01 positive uveal melanoma
31 Mar 2022
Cancer Immunology and Immunotherapy;  Melanoma and other skin tumours

On 24 February 2022, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product tebentafusp (Kimmtrak), intended for the treatment of uveal melanoma. Kimmtrak was reviewed under EMA’s accelerated assessment programme.

The applicant for this medicinal product is Immunocore Ireland Limited.

Kimmtrak will be available as a 100 mcg/0.5 mL concentrate for solution for infusion. The active substance of Kimmtrak is tebentafusp, an antineoplastic agent (ATC code: L01) with bispecific affinity, targeting the CD3 T cells and a gp100 peptide on the surface of uveal melanoma tumour cells. This redirects and activates T cells and results in direct lysis of uveal melanoma tumour cells.

The benefits of Kimmtrak are a gain in median overall survival of 5.7 months over the investigator’s choice treatment as observed in a randomised, open label, multicentre pivotal study.

The most common side effects are cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, oedema, hypo/hyperpigmentation, hypotension, dry skin, headache and vomiting.

The full indication is:

Kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (HLA) A*02:01 positive adult patients with unresectable or metastatic uveal melanoma.

Kimmtrak should be administered under the direction and supervision of a physician experienced in the use of anticancer agents and who is prepared to manage cytokine release syndrome in an environment where full resuscitation facilities are immediately available.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.

This product was designated as an orphan medicine during its development. EMA will now review the information available to date to determine if the orphan designation can be maintained.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.